Drug Trial Radar · NCT03512756
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
130
Actual
Start
Mar 27, 2018
Primary completion
Dec 28, 2021
Study completion Dec 28, 2021
Sponsor
- Lead sponsor
- Tyme, IncIndustry
- Sponsor type
- Industry
- First posted
- May 1, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A prospective, open-label phase 2/3 trial in metastatic pancreatic cancer participants who have failed two lines of prior systemic therapy. The trial is designed to evaluate the safety and efficacy of SM-88 used with MPS (methoxsalen, phenytoin and sirolimus) in pancreatic cancer and will measure multiple endpoints, including overall survival, progression free survival, relevant biomarkers, quality of life, safety, and overall response rate. (Part 1 enrollment complete) In the initial stage of the trial (36 participants), two dose levels of SM-88's metyrosine-derivative was evaluated. (Part 2 actively enrolling) The second part will consist of a subsequent expansion of the trial to further assess safety and efficacy of SM-88 used with MPS containing the selected SM-88 RP2D from Part 1. A total of 250 participants in the second part will be randomized 1:1 either to the SM-88 arm (125 participants) or Physician's Choice of therapy for the Control Arm (125 participants). Participants should have previously received two lines of prior systemic therapy.
Conditions
- Pancreatic Cancer
Interventions
SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)Drug
Daily oral therapy for cancer
Capecitabine, Gemcitabine, and 5-FUDrug
Investigator choice of the following therapies: Capecitabine, Gemcitabine, and 5-FU
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to 12 months
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
City Of Hope
Duarte, California
Sarcoma Oncology Research Center
Santa Monica, California
Hartford Healthcare Cancer
New Britain, Connecticut
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Advent Health Florida Hospital Tampa
Tampa, Florida
June E. Nylen Cancer Center
Sioux City, Iowa
University Medical Center
New Orleans, Louisiana
Karmanos Cancer Institute
Detroit, Michigan
Washington University
St Louis, Missouri
North Shore Hematology Oncology
East Setauket, New York
NY Cancer and Blood Specialist
East Setauket, New York
NYU Langone Health
New York, New York
Central Park Hematology & Oncology
New York, New York
Weill Cornell
New York, New York
New York Cancer and Blood Specialist
The Bronx, New York
The Ohio State University
Columbus, Ohio
Texas Oncology-Baylor
Dallas, Texas
MD Anderson
Houston, Texas
Virginia Mason Medical Center
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.